The opioid medications codeine and hydrocodone, commonly prescribed in sickle cell disease (SCD), require metabolic conversion by cytochrome P450 2D6 (CYP2D6) to morphine and hydromorphone, respectively, to exert their analgesic effects. The CYP2D6 gene is highly polymorphic, with variant alleles that result in decreased, absent, or ultrarapid enzyme activity. Seventy-five children with SCD were tested for CYP2D6 polymorphisms, and metabolic phenotypes were inferred from the genotypes. The most common variant alleles were CYP2D6*2 (normal activity, 28.7%), CYP2D6*17 (reduced activity, 17.3%), CYP2D6*5 (gene deletion, 8.7%), and CYP2D6*4 (absent function, 8.0%). Normal/extensive metabolizer (EM) genotypes were found in 28/75 (37.5%), intermediate metabolism (IM) in 33/75 (44.0%), poor metabolism (PM) in 4/75 (5.3%), ultrarapid metabolism (UM) in 3/75 (4.0%), indeterminate in 6/75 (8.0%). Allele frequencies did not vary significantly among different hemoglobin genotypes. Identification of variant CYP2D6 genotypes may identify individuals with altered metabolism and therefore altered analgesic response to codeine and hydrocodone, thus providing a personalized medicine approach to treatment of pain in SCD. Further pharmacokinetic and pharmacodynamic studies are needed to define the relationship of CYP2D6 and other gene polymorphisms to individual opioid effect in SCD.
Introduction
Opioid analgesic medications are a mainstay of treatment for mild to moderate vasoocclusive crisis (VOC) in sickle cell disease (SCD), and nearly all SCD patients will have exposure to these medications at some point during childhood. The commonly prescribedopioids codeine and hydrocodone are inactive prodrugs which require in vivo Odemethylation by the hepatic enzyme cytochrome P450 2D6 (CYP2D6) to the active analgesics morphine and hydromorphone, respectively [1] [2] [3] . Although CYP2D6 metabolism is a minor pathway of codeine metabolism, representing only 5 -10% of codeine clearance, it is a required initial step for the opioid's analgesic effect [2] . Clinical response to opioid medications varies among individuals for numerous reasons, including drug bioavailability and distribution, genetic polymorphisms in metabolizing enzymes and opioid receptors, and the pharmacokinetics of drug clearance [4] . With personalized medicine, genetic information, such as CYP2D6 polymorphisms, may be used to predict the metabolism of specific medications, thus providing information about drug efficacy for individual patients.
CYP2D6 is encoded by a highly polymorphic gene on chromosome 22 and has over 80 known variant alleles described to-date (listed at http://www.cypalleles.ki.se/cyp2d6.htm). The wild type CYP2D6 allele is denoted as *1, with variant alleles noted as *2, *3, etc [5] .
Combinations of single nucleotide polymorphisms (SNPs) may result in gene products with normal, decreased, or non-functional enzyme activity. CYP2D6 genotypes can be categorized into phenotypic groups based on the variant enzymes' activity. Extensive metabolizers (EM) have normal enzyme activity; this includes individuals with 2 normal function alleles and some heterozygotes with normal and decreased activity alleles. Intermediate metabolizers (IM) have decreased enzyme activity; typically this is due to heterozygosity for a non-functional allele or homozygosity for two decreased activity alleles. Poor metabolizers (PM) have absent or little enzyme activity; this is due to homozygosity or compound heterozygosity for two non-functional alleles. Ultra-rapid metabolizers (UM) have greater than normal activity and are the result of duplications of active alleles [2, 6] . The UM phenotype leads to rapid clearance of the substrate drug, thus providing minimal or brief therapeutic effect and/or abrupt drug toxicity [7] [8] [9] .
The frequency of CYP2D6 polymorphisms and phenotypes varies significantly among different racial and ethnic populations, and studies of CYP2D6 polymorphisms within the U.S. sickle cell population to date have been limited to examining a small number of variant alleles. A study by Brousseau et al. of 73 SCD children presenting with VOC unrelieved by oral codeine found that 58% had at least one reduced or non-functional allele [10] . A genotyping study by Joly et al. showed reduced CYP2D6 metabolic activity in the majority of patients [11] ; however to date, there are no studies of CYP2D6 genotypes prevalence in the African-American SCD population. The aim of this study was to determine the frequency of CYP2D6 alleles and genotypes in an unselected cohort of children with SCD by testing for the most common SNPs described in the U.S. and African-American populations.
Materials and Methods
Children ages 6 to 18 years with SCD of any genotype who presented to Children's Healthcare of Atlanta (CHOA) for outpatient care were offered study participation. Subjects were enrolled competitively over a 4 month period from March -July 2009 without selection or exclusion criteria other than subject or guardian refusal. This study was approved by the Institutional Review Boards (IRB) of Emory University and CHOA. Written, informed consent was obtained to test CYP2D6 polymorphisms using previously collected, discarded blood specimens. To eliminate the chance of sampling foreign DNA from recent blood transfusions, patients were excluded if they had received blood transfusion within the prior 48 hours.
CYP2D6 Genotyping and Phenotype Inference
DNA was extracted from whole blood specimens using the MagnaPureLC System (Roche Applied Science, Indianapolis, IN). Single multiplex polymerase chain reaction (PCR) was performed to identify the following 16 SNPs in CYP2D6 using the xTag 2D6 (Luminex Corp., Austin, TX): 1548 C>G, 1661 G>C, 2850 C>T, 4180 G>C, 2549 delA, 100 C>G, 1846 G>A, 1707 delT, 2935 A>C, 1758 G>T, 2613 delAGA, 883 G>C, 124 G>A, 138 insT, 1023 C>T, 2877 G>A. Additionally, gene deletion (allele *5) and gene duplications were detected. The combination of these SNPs and mutations allowed for the identification of 2 active alleles (*1 or wild type and *2), 4 decreased activity alleles (*9, *10, *17, *41), and 10 non-functional alleles (*3, *4, *5, *6, *7, *8 or *14, *11, *12, *15). Because some SNPs are shared among numerous variant alleles, determination of the CYP2D6 allele was based on combinations of several identified SNPs. If no SNPs were detected, the subject was assumed to be homozygous for the *1 wild type allele. The presence of multiple gene copies was tested; in instances of compound heterozygous genotypes with gene duplication, testing did not distinguish which allele had multiple gene copies.
For each genotype found in this study, the corresponding known enzymatic phenotype was assigned. The clinical phenotypes of enzyme activity for each CYP2D6 allele, based on in vivo drug metabolism studies, have been previously described [6] . The presence of two functional alleles confers the EM phenotype, two non-functional alleles confer the PM phenotype, and two decreased activity alleles confer the IM phenotype. Individuals who are heterozygous for a functional allele and a decreased activity allele may have either the EM or IM phenotype. For example, the combination of a functional allele with *17 (reduced function allele) produces the IM phenotype, while the combination of a functional allele with the *10 or *41 reduced function alleles results in the EM phenotype [6, 12, 13] . In all cases possible, predicted phenotypes were assigned based on previously established drug metabolism studies for each genotype [6] .
Statistical Analysis
Descriptive methods were used to present CYP2D6 allele frequencies and genotype frequencies. Allele frequencies were determined from the cohort's genotypes. For each individual, a genotype of 2 alleles was determined, thus the frequency of each allele was calculated using the denominator of 2-times the total number of subjects in the cohort. The frequency of each CYP2D6 phenotype among children of different hemoglobin genotypes was compared by Fisher's exact test.
Results
CYP2D6 allele testing was performed in 75 children with SCD: 51 (68.0%) HbSS, 15 (20.0%) HbSC, 4 (4.3%) HbS + thalassemia (HbS + ), 5 (6.7%) HbS 0 thalassemia (HbS 0 ). Racial and ethnic backgrounds were African-American in 73/75 and African in 2/75. The mean age was 12.5 years (range 6.3 -18.8 years). There were 39 subjects on hydroxyurea (HU) and 5 subjects on chronic transfusions at the time of the study (2 subjects were receiving HU and transfusions concurrently).
CYP2D6 allele frequencies for the cohort are shown in Table I . The most prevalent alleles were the wild type allele *1 (30.7%) and the normal/increased activity allele *2 (28.7%). The frequency of decreased function alleles (*10, *17, *41) was 36/150 (24.0%), and the frequency of non-functional alleles (*4, *5) was 25/150 (16.6%). Among the alleles that convey abnormal CYP2D6 activity, *17 was the most prevalent (allele frequency 17.3%; genotype frequencies: 26.7% heterozygous, 4.0% homozygous subjects). Nine subjects had allele duplications: 3 with the UM predicted phenotype and 6 for whom phenotype was indeterminate due to the fact that these subjects were compound heterozygous for normal and reduced activity alleles. Alleles *3, *6, *7, *8, *9, *11, *12, and *15 which are rare in African-American populations (allele frequencies <1%), were not present in this cohort [2, 6] .
CYP2D6 genotype frequencies and predicted phenotypes are shown in Table II . The reduced activity phenotypes IM and PM represented a larger proportion of the study group than the normal activity EM phenotype. The most common phenotype was IM (33/75, 44.0%), followed by EM (28/75, 37.3%), PM (5/75, 6.7%), and UM (3/75, 4.0%). Because the genotype assay detected the presence of gene duplication but does not specify which allele is duplicated, phenotypes could not be inferred for 6 (8.0%) compound heterozygotes. Of these 6 subjects, 3 were heterozygous for a normal activity and a reduced/absent function allele (predicted phenotype of either UM or IM) and 3 were heterozygous for a non-functional allele and a reduced function allele (predicted phenotype of either PM or greater metabolic activity) [8] . Thus, the range of possible CYP2D6 phenotypes in this SCD cohort is: 37.3 -41.3% IM; 44.0 -48.0% EM; 5.3 -9.3% PM; 4.0 -8.0% UM. Figure 1 compares the frequency of predicted CYP2D6 phenotypes for each Hb genotype. There were no significant differences in either allele frequencies or predicted genotypes among subjects with HbSS, HbSC, HbS + and HbS 0 (data not shown).
Discussion
This study shows that a large proportion of SCD patients have variant CYP2D6 genotypes that confer altered enzyme activity, thus potentially altering the normal pharmacokinetics and analgesic efficacy of the opioid medications codeine and hydrocodone. The CYP2D6 allele frequencies in this cohort of SCD patients are similar to ranges reported in other U.S. African-American populations, with a slightly higher frequency of CYP2D6 gene deletions [2, 6, 14, 15] .
Inadequate analgesic response to codeine or hydrocodone during sickle cell vaso-occlusive pain crises is a common reason for hospitalization. Many factors contribute to opioid analgesia, including the pharmacokinetics of drug bioavailability and clearance, drug metabolic activation, opioid receptor response, and transport of drug metabolites across the blood brain barrier. For codeine and hydrocodone, CYP2D6 activity is the required first step in the pathway of opioid analgesic effect, converting the prodrug to morphine or hydromorphone, respectively. The high frequency of variant CYP2D6 genotypes in this cohort of pediatric SCD patients suggests that altered CYP2D6 activity is common in this population, possibly contributing to failure of analgesic response to codeine and hydrocodone in some patients. Thus CYP2D6 genetic testing should be considered in patients with repeated episodes of failed outpatient pain management,. Patients with genotypes that confer the PM and UM phenotypes will not respond to codeine or hydrocodone for pain relief, due to either the inability to convert these drugs into active analgesics (PM phenotype) or rapid drug activation and clearance, leading to potential rapid drug toxicity and ineffective analgesia (UM phenotype) [2] . Patients with the IM phenotype have some ability to produce active metabolites from codeine and hydrocodone; however these patients may not be able to achieve adequate analgesia with standard dosing and may require higher doses for therapeutic effect. Opioid medications that do not require enzymatic activation, such as morphine or hydromorphone may produce better analgesia in these patients.
CYP2D6 genotype is only one factor that affects opioid metabolic phenotype. CYP2D6 is involved in the metabolism of approximately 25% of all medications [16] , and its activity may be inhibited or induced by many common medications, such as H1 histamine receptor antagonists, selective serotonin release inhibitors, and methadone, leading to abnormal metabolism of codeine and hydrocodone [17, 18] . Following enzymatic activation by CYP2D6, several other factors affect morphine and hydromorphone's analgesic effects. Darbari et al. demonstrated that morphine clearance is significantly higher in SCD as compared to non-SCD individuals, and may be related to increased hepatic metabolism and increased renal elimination that are unique to SCD [19] . Thus, SCD patients may require higher and more frequent opioid doses to maintain adequate concentrations for analgesia, independent of CYP2D6 genotype. Additionally, variability in other genes that regulate opioid pharmacokinetics and pharmacodynamics, such as UDP-glucuronosyltransferase (responsible for morphine metabolism), the 03bc opioid receptor, and blood-brain-barrier transporter proteins, may decrease opioid efficacy or potentially promote opioid addiction [3, 4, 20] . Given the numerous confounding variables that affect both CYP2D6 metabolic phenotype and opioid efficacy, further studies examining the associations of genetic variation in CYP2D6 and other genes, codeine pharmacokinetics, and patient-reported analgesic effects are necessary.
A limitation of this study was the inability to identify less common CYP2D6 alleles.
Although the array of SNPs tested in this study allowed for the identification of 16 of the most common variant alleles, other less common alleles were not detectable by the study assay. Subjects who did not have one of the 16 tested SNPs for were assumed to have the *1 wild type allele, thus rare SNPs and alleles may have been missed inadvertently. Discordance between CYP2D6 genotype and phenotype has been observed in African populations, and may be due to unrecognized polymorphisms [15, [21] [22] [23] . Our study also was limited by the ability to accurately determine the genotypes of a few individuals with gene duplications. Because we assayed for gene duplications by identifying CYP2D6 gene sequences shared among different alleles, for individuals who are compound heterozygotes and have gene duplication, it was not possible to determine which variant allele is overexpressed by the methods used in this study.
In summary, pharmacologic pain management in SCD depends on numerous factors, including drug pharmacokinetics, pharmacogenetics of metabolizing enzymes including CYP2D6, and allelic variation in other genes involved in opioid efficacy, such as the opioid receptor.. Because there is a high frequency of variant CYP2D6 metabolizers in the African-American SCD population, clinicians should be aware that genetic variation in the CYP2D6 gene may contribute to poor analgesic responses to common pain medications prescribed for outpatient SCD pain management. With personalized medicine, genetic testing allows clinicians to predict response to medications and customize individual treatments based on genetic polymorphisms. Larger studies of CYP2D6 genotypes, codeine and hydrocodone pharmacokinetics, and pharmacodynamic measurements of opioid efficacy are needed to further define the extent to which CYP2D6 phenotype contributes to failed outpatient management of pain in the SCD population. 
